Clinical outcomes and safety of patients treated with NAb-Paclitaxel plus Gemcitabine in metastatic pancreatic cancer: the NAPA study.

CONCLUSIONS: Our results confirm the efficacy and safety of a first line regimen comprising gemcitabine and Nab-paclitaxel in metastatic PDAC in a real-life population.
PMID: 32957885 [PubMed - as supplied by publisher]

Source: Current Cancer Drug Targets - September 17, 2020 Category: Cancer & Oncology Authors: Catalano M, Roviello G, Conca R, D'Angelo A, Palmieri VE, Panella B, Petrioli R, Ianza A, Nobili S, Mini E, Ramello M Tags: Curr Cancer Drug Targets Source Type: research